

Abington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	16.0	112.2	(66.4-177.3)	Male	9	11.3	79.7	(36.4-151.3)
Female	6	5.8	103.6	(37.8-225.4)	Female	15	9.0	166.7	(93.2-275.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.4	nc	(nc-nc)	Male	2	2.9	nc	(nc-nc)
Female	4	2.8	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	13	9.8	132.5	(70.5-226.5)
Female	63	64.5	97.7	(75.1-125.0)	Female	10	7.9	127.1	(60.9-233.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.5	nc	(nc-nc)	Male	8	7.5	106.5	(45.9-209.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	19	19.7	96.3	(57.9-150.3)	Female	9	5.9	153.4	(70.0-291.2)
Female	20	19.0	105.0	(64.1-162.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	5.4	nc	(nc-nc)
Male	6	4.6	129.6	(47.3-282.1)	Female	9	5.7	158.1	(72.2-300.2)
Female	2	1.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	58	69.4	83.6	(63.5-108.1)
Male	3	1.5	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.2	nc	(nc-nc)	Male	3	3.9	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	2.3	nc	(nc-nc)
Male	17	9.5	179.2	(104.4-287.0)	<u>Testis</u>				
Female	9	5.2	172.7	(78.8-327.8)	Male	2	2.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	2.7	nc	(nc-nc)	Male	3	4.1	nc	(nc-nc)
Female	3	0.8	nc	(nc-nc)	Female	16	12.5	128.4	(73.4-208.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	6.3	79.1	(25.5-184.5)	Female	13	14.7	88.2	(46.9-150.9)
Female	6	4.7	128.9	(47.1-280.6)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	243	233.6	104.0	(91.4-118.0)
Male	4	5.4	nc	(nc-nc)	Female	255	220.3	115.8	(102.0-130.9)
Female	2	1.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	44	30.2	145.9	(106.0-195.9)					
Female	43	30.6	140.6	(101.7-189.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Acton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	17.6	102.2	(60.5-161.5)	Male	17	12.8	132.9	(77.4-212.8)
Female	8	6.3	126.2	(54.4-248.8)	Female	11	11.0	100.3	(50.0-179.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	4.1	172.4	(69.1-355.2)	Male	3	3.2	nc	(nc-nc)
Female	2	3.4	nc	(nc-nc)	Female	5	2.5	197.9	(63.8-461.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	10	11.3	88.2	(42.2-162.3)
Female	98	81.4	120.4	(97.8-146.8)	Female	12	9.1	132.6	(68.4-231.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	3.3	nc	(nc-nc)	Male	6	8.6	69.5	(25.4-151.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	17	22.2	76.7	(44.7-122.8)	Female	13	7.2	181.7	(96.7-310.8)
Female	18	21.3	84.4	(50.0-133.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	7	5.9	118.3	(47.4-243.7)
Male	3	5.1	nc	(nc-nc)	Female	8	6.2	129.2	(55.6-254.6)
Female	1	1.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	79	73.8	107.1	(84.8-133.5)
Male	1	1.7	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.4	nc	(nc-nc)	Male	1	4.4	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	4	2.5	nc	(nc-nc)
Male	11	10.9	100.8	(50.3-180.4)	<u>Testis</u>				
Female	3	6.2	nc	(nc-nc)	Male	3	2.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	3.0	nc	(nc-nc)	Male	4	4.9	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	11	16.3	67.4	(33.6-120.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	7.2	83.0	(30.3-180.6)	Female	23	18.3	125.8	(79.7-188.8)
Female	9	5.4	166.5	(76.0-316.1)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	226	258.2	87.5	(76.5-99.7)
Male	1	6.1	nc	(nc-nc)	Female	272	263.3	103.3	(91.4-116.4)
Female	1	2.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	17	33.0	51.5	(30.0-82.4)					
Female	20	34.2	58.5	(35.7-90.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Acushnet

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	12.2	98.3	(50.7-171.7)	Male	10	7.9	125.9	(60.3-231.5)
Female	5	4.3	115.4	(37.2-269.2)	Female	6	6.3	95.3	(34.8-207.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	2.3	219.2	(70.7-511.6)	Male	2	2.1	nc	(nc-nc)
Female	0	1.9	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	8	7.0	114.7	(49.4-226.0)
Female	48	46.3	103.8	(76.5-137.6)	Female	3	5.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.7	nc	(nc-nc)	Male	5	5.1	97.9	(31.5-228.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	18	14.3	126.2	(74.8-199.5)	Female	4	4.2	nc	(nc-nc)
Female	20	14.1	141.6	(86.5-218.8)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	3	3.3	nc	(nc-nc)	Male	65	48.0	135.5	(104.6-172.7)
Female	1	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	3	0.9	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	8	6.6	121.9	(52.5-240.3)	Female	7	10.6	65.8	(26.4-135.6)
Female	5	3.8	131.5	(42.4-306.9)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	4	1.9	nc	(nc-nc)	Male	5	4.6	109.3	(35.2-255.0)
Female	2	0.6	nc	(nc-nc)	Female	3	3.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	4	3.6	nc	(nc-nc)	Male	29	22.2	130.4	(87.3-187.3)
Female	0	1.3	nc	(nc-nc)	Female	18	22.9	78.5	(46.5-124.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Adams

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	10.1	139.2	(76.0-233.5)	Male	8	6.4	124.5	(53.6-245.3)
Female	5	4.6	108.6	(35.0-253.5)	Female	3	5.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.8	nc	(nc-nc)	Male	4	1.7	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	10	5.6	177.0	(84.7-325.6)
Female	31	42.2	73.5	(49.9-104.3)	Female	6	5.8	103.7	(37.9-225.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.4	nc	(nc-nc)	Male	3	4.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	20	11.7	171.4	(104.6-264.7)	Female	4	4.0	nc	(nc-nc)
Female	15	15.0	100.0	(55.9-165.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	3.3	152.9	(49.3-356.8)
Male	3	2.7	nc	(nc-nc)	Female	5	4.6	109.2	(35.2-254.8)
Female	1	1.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	61	39.9	153.0	(117.0-196.6)
Male	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.7	nc	(nc-nc)	Male	3	2.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	1.8	nc	(nc-nc)
Male	5	5.3	94.7	(30.5-221.1)	<u>Testis</u>				
Female	3	3.6	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.6	nc	(nc-nc)	Male	0	2.1	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	2	6.8	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	3.7	nc	(nc-nc)	Female	9	9.7	93.1	(42.5-176.7)
Female	1	3.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	176	136.1	129.3	(110.9-149.9)
Male	2	3.1	nc	(nc-nc)	Female	140	154.1	90.9	(76.4-107.2)
Female	0	1.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	25	18.5	135.2	(87.5-199.7)					
Female	36	23.2	155.0	(108.6-214.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Agawam

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	34	37.2	91.3	(63.2-127.6)	Male	21	23.2	90.6	(56.1-138.6)
Female	19	14.5	131.2	(79.0-205.0)	Female	10	18.9	52.9	(25.3-97.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	6.5	138.5	(63.2-262.9)	Male	2	6.2	nc	(nc-nc)
Female	7	5.9	118.7	(47.6-244.6)	Female	4	5.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.2	nc	(nc-nc)	Male	21	20.8	101.2	(62.6-154.6)
Female	152	136.9	111.0	(94.1-130.2)	Female	17	18.3	92.7	(53.9-148.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	7	4.8	145.0	(58.1-298.9)	Male	16	14.6	109.5	(62.5-177.8)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	48	43.0	111.7	(82.4-148.2)	Female	14	12.9	108.3	(59.2-181.7)
Female	56	47.9	116.8	(88.2-151.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	9	11.9	75.8	(34.6-143.8)
Male	11	9.4	116.6	(58.1-208.6)	Female	9	14.4	62.4	(28.5-118.5)
Female	4	3.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	116	130.9	88.6	(73.2-106.3)
Male	0	2.6	nc	(nc-nc)	<u>Stomach</u>				
Female	7	2.3	310.3	(124.3-639.3)	Male	16	8.6	185.5	(106.0-301.2)
<u>Kidney & Renal Pelvis</u>					Female	5	5.9	85.3	(27.5-199.1)
Male	16	18.7	85.4	(48.8-138.7)	<u>Testis</u>				
Female	11	11.5	95.7	(47.7-171.2)	Male	3	3.9	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	5.4	nc	(nc-nc)	Male	8	7.5	106.8	(46.0-210.5)
Female	1	1.7	nc	(nc-nc)	Female	18	22.9	78.6	(46.5-124.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	13.6	nc	(nc-nc)	Female	24	31.2	77.0	(49.3-114.6)
Female	7	10.8	64.9	(26.0-133.7)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	456	479.3	95.1	(86.6-104.3)
Male	3	10.7	nc	(nc-nc)	Female	480	493.1	97.3	(88.8-106.4)
Female	2	4.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	77	65.2	118.1	(93.2-147.6)					
Female	64	71.3	89.8	(69.1-114.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Alford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.1	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	3	2.6	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	1.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	4.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.5	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Male</u>				
Male	0	0.2	nc	(nc-nc)	9	13.4	66.9	(30.5-127.1)	
Female	0	0.0	nc	(nc-nc)	<u>Female</u>				
<u>Leukemia</u>					5				
Male	0	0.4	nc	(nc-nc)	8.9	55.9	(18.0-130.6)		
Female	0	0.2	nc	(nc-nc)					
<u>Liver and Intrahepatic Bile Ducts</u>									
Male	0	0.3	nc	(nc-nc)					
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	0	1.9	nc	(nc-nc)					
Female	0	1.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Amesbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	22	13.9	158.4	(99.3-239.9)	Male	17	10.1	168.3	(98.0-269.5)
Female	5	6.1	81.5	(26.3-190.2)	Female	16	9.4	170.3	(97.3-276.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	3.1	159.2	(51.3-371.6)	Male	5	2.5	197.2	(63.5-460.1)
Female	5	2.9	171.8	(55.3-400.8)	Female	3	2.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	14	8.9	157.8	(86.2-264.7)
Female	79	67.4	117.3	(92.8-146.1)	Female	13	8.3	157.2	(83.6-268.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.6	nc	(nc-nc)	Male	13	6.8	191.3	(101.7-327.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	21	17.5	120.0	(74.2-183.4)	Female	6	6.2	97.5	(35.6-212.3)
Female	28	20.5	136.8	(90.9-197.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	6	4.7	128.1	(46.8-278.9)
Male	7	4.0	173.8	(69.6-358.1)	Female	4	6.1	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	50	59.4	84.2	(62.5-111.0)
Male	1	1.5	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.2	nc	(nc-nc)	Male	0	3.4	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	2.5	nc	(nc-nc)
Male	4	8.5	nc	(nc-nc)	<u>Testis</u>				
Female	3	5.4	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	2.4	nc	(nc-nc)	Male	1	3.9	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	7	12.9	54.2	(21.7-111.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	10	5.7	176.6	(84.6-324.9)	Female	15	15.2	98.7	(55.2-162.8)
Female	4	4.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	235	205.1	114.6	(100.4-130.2)
Male	4	4.8	nc	(nc-nc)	Female	261	230.9	113.0	(99.7-127.6)
Female	4	1.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	37	26.1	141.5	(99.6-195.0)					
Female	37	31.6	117.0	(82.4-161.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Amherst

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	19.1	78.4	(43.9-129.4)	Male	9	13.7	65.6	(29.9-124.6)
Female	6	7.5	79.7	(29.1-173.6)	Female	11	13.7	80.2	(40.0-143.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	4.8	nc	(nc-nc)	Male	1	3.3	nc	(nc-nc)
Female	4	4.5	nc	(nc-nc)	Female	2	2.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	10	12.7	78.6	(37.6-144.5)
Female	83	77.8	106.7	(85.0-132.3)	Female	14	10.6	131.6	(71.9-220.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	3.2	nc	(nc-nc)	Male	10	8.9	112.7	(54.0-207.3)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	14	22.8	61.4	(33.5-103.0)	Female	10	7.9	126.6	(60.6-232.8)
Female	19	25.1	75.7	(45.6-118.2)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	2	5.3	nc	(nc-nc)	Male	76	79.1	96.1	(75.7-120.2)
Female	0	1.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	3.9	nc	(nc-nc)	Male	3	6.2	nc	(nc-nc)
Female	1	3.7	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	9	10.8	83.6	(38.1-158.7)	Female	10	18.0	55.5	(26.6-102.0)
Female	3	6.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	2	3.1	nc	(nc-nc)	Male	9	8.5	105.6	(48.2-200.4)
Female	2	0.9	nc	(nc-nc)	Female	4	6.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	4	6.2	nc	(nc-nc)	Male	13	35.0	37.1	(19.8-63.5)
Female	2	2.2	nc	(nc-nc)	Female	21	38.3	54.9	(34.0-83.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Andover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	35	34.9	100.3	(69.9-139.6)	Male	22	23.6	93.1	(58.3-140.9)
Female	11	12.7	86.6	(43.2-154.9)	Female	21	19.0	110.4	(68.3-168.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	7.0	85.3	(31.1-185.7)	Male	9	6.2	144.6	(66.0-274.6)
Female	5	5.9	84.2	(27.1-196.4)	Female	2	4.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.1	nc	(nc-nc)	Male	23	20.8	110.8	(70.2-166.3)
Female	132	140.6	93.9	(78.5-111.3)	Female	21	17.1	123.1	(76.2-188.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	5.3	nc	(nc-nc)	Male	19	15.6	121.6	(73.2-189.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	29	41.7	69.6	(46.6-99.9)	Female	21	12.8	164.5	(101.8-251.5)
Female	30	42.4	70.7	(47.7-100.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	9	11.6	77.6	(35.4-147.3)
Male	11	9.8	112.6	(56.2-201.6)	Female	12	12.5	95.7	(49.4-167.1)
Female	5	2.6	189.1	(60.9-441.3)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	143	143.4	99.7	(84.0-117.4)
Male	3	2.8	nc	(nc-nc)	<u>Stomach</u>				
Female	3	2.4	nc	(nc-nc)	Male	13	8.3	156.6	(83.3-267.8)
<u>Kidney & Renal Pelvis</u>					Female	3	5.1	nc	(nc-nc)
Male	13	19.9	65.4	(34.8-111.8)	<u>Testis</u>				
Female	9	11.2	80.2	(36.6-152.2)	Male	6	4.2	142.8	(52.2-310.9)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	5.7	nc	(nc-nc)	Male	10	8.3	121.0	(57.9-222.6)
Female	1	1.7	nc	(nc-nc)	Female	32	25.7	124.6	(85.2-175.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	18	13.3	135.3	(80.1-213.8)	Female	39	31.8	122.7	(87.2-167.7)
Female	11	10.1	108.7	(54.2-194.6)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	445	490.8	90.7	(82.4-99.5)
Male	11	11.4	96.5	(48.1-172.8)	Female	442	477.5	92.6	(84.1-101.6)
Female	1	3.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	30	65.2	46.0	(31.0-65.6)					
Female	47	65.6	71.6	(52.6-95.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Aquinnah

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	1	0.1	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
					Male	5	6.0	83.8	(27.0-195.6)
					Female	3	4.6	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Arlington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	44	44.6	98.7	(71.7-132.5)	Male	36	29.5	121.8	(85.3-168.7)
Female	19	20.2	94.3	(56.7-147.2)	Female	36	28.0	128.7	(90.1-178.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	8.6	93.1	(40.1-183.5)	Male	9	7.8	116.0	(52.9-220.1)
Female	6	8.6	69.5	(25.4-151.3)	Female	8	7.6	104.7	(45.1-206.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.4	nc	(nc-nc)	Male	24	25.9	92.7	(59.4-137.9)
Female	226	200.4	112.8	(98.5-128.5)	Female	29	26.1	111.0	(74.3-159.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	7.5	nc	(nc-nc)	Male	16	18.6	85.9	(49.0-139.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	52	52.9	98.3	(73.4-129.0)	Female	20	18.6	107.5	(65.6-166.0)
Female	66	66.3	99.5	(77.0-126.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	11	14.5	75.8	(37.8-135.6)
Male	15	11.8	126.7	(70.9-209.0)	Female	21	20.0	105.0	(65.0-160.5)
Female	4	4.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	141	170.9	82.5	(69.5-97.3)
Male	2	3.5	nc	(nc-nc)	<u>Stomach</u>				
Female	4	3.4	nc	(nc-nc)	Male	9	10.5	85.7	(39.1-162.8)
<u>Kidney & Renal Pelvis</u>					Female	3	8.0	nc	(nc-nc)
Male	29	24.2	119.9	(80.3-172.3)	<u>Testis</u>				
Female	14	16.8	83.3	(45.5-139.8)	Male	7	5.9	118.2	(47.4-243.6)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	6.9	nc	(nc-nc)	Male	10	10.1	99.0	(47.4-182.0)
Female	3	2.4	nc	(nc-nc)	Female	33	36.0	91.7	(63.1-128.8)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	17	16.7	101.7	(59.2-162.9)	Female	41	45.3	90.5	(64.9-122.7)
Female	19	15.4	123.6	(74.4-193.1)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	565	605.4	93.3	(85.8-101.3)
Male	13	13.7	94.8	(50.4-162.2)	Female	729	711.8	102.4	(95.1-110.1)
Female	5	5.7	88.0	(28.4-205.3)					
<u>Lung and Bronchus</u>									
Male	74	81.4	90.9	(71.4-114.1)					
Female	94	102.9	91.3	(73.8-111.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ashburnham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	4.7	147.4	(59.1-303.7)	Male	1	3.8	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	Female	5	2.9	169.9	(54.7-396.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.2	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.2	nc	(nc-nc)
Female	19	21.4	88.6	(53.3-138.3)	Female	4	2.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.9	nc	(nc-nc)	Male	0	2.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	6.2	nc	(nc-nc)	Female	0	1.9	nc	(nc-nc)
Female	7	5.5	127.8	(51.2-263.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	1.7	nc	(nc-nc)
Male	3	1.6	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	22	24.8	88.8	(55.7-134.5)
Male	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	0.6	nc	(nc-nc)
Male	2	3.3	nc	(nc-nc)	<u>Testis</u>				
Female	1	1.6	nc	(nc-nc)	Male	3	0.8	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.9	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	3	4.5	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	2.0	nc	(nc-nc)	Female	6	4.8	124.7	(45.5-271.4)
Female	1	1.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	65	78.0	83.3	(64.3-106.2)
Male	1	2.0	nc	(nc-nc)	Female	74	69.1	107.1	(84.1-134.5)
Female	0	0.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	3	9.4	nc	(nc-nc)					
Female	11	8.9	123.7	(61.6-221.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ashby

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	2.5	199.1	(64.2-464.7)	Male	2	1.9	nc	(nc-nc)
Female	3	0.9	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.6	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	2	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	9	11.3	79.6	(36.3-151.0)	Female	4	1.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	3.2	nc	(nc-nc)	Female	3	1.0	nc	(nc-nc)
Female	2	3.0	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	0.9	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	11	10.5	104.7	(52.2-187.4)
Male	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.4	nc	(nc-nc)
Male	0	1.6	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.9	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	0.4	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.0	nc	(nc-nc)	Female	5	2.5	196.9	(63.5-459.6)
Female	3	0.8	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	36	37.1	97.1	(68.0-134.4)
Male	0	0.9	nc	(nc-nc)	Female	41	37.0	110.8	(79.5-150.4)
Female	1	0.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	6	4.8	125.3	(45.8-272.7)					
Female	2	4.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ashfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.4	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	Female	3	1.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	3	0.9	nc	(nc-nc)
Female	14	8.5	164.4	(89.8-275.9)	Female	1	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.3	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	1.8	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	1	2.3	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.5	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	10	6.5	153.3	(73.4-281.9)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.3	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.7	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.6	nc	(nc-nc)	Female	4	2.0	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	26	21.6	120.6	(78.8-176.8)
Male	0	0.5	nc	(nc-nc)	Female	29	27.9	103.8	(69.5-149.0)
Female	0	0.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	2	2.6	nc	(nc-nc)					
Female	1	3.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ashland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	13.2	128.5	(74.8-205.7)	Male	9	9.6	93.3	(42.6-177.2)
Female	5	5.0	100.5	(32.4-234.4)	Female	5	8.6	58.2	(18.8-135.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.0	nc	(nc-nc)	Male	6	2.4	246.5	(90.0-536.5)
Female	2	2.7	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	6	8.4	71.0	(25.9-154.6)
Female	64	62.3	102.7	(79.1-131.2)	Female	6	7.1	84.6	(30.9-184.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.6	nc	(nc-nc)	Male	5	6.5	77.5	(25.0-180.8)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	9	16.4	54.9	(25.0-104.2)	Female	12	5.5	217.2	(112.1-379.4)
Female	19	16.5	115.3	(69.4-180.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	7	4.4	157.5	(63.1-324.4)
Male	5	3.8	131.8	(42.5-307.7)	Female	4	4.9	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	68	54.8	124.2	(96.4-157.4)
Male	1	1.3	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1.1	nc	(nc-nc)	Male	4	3.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	1.9	nc	(nc-nc)
Male	11	8.1	135.1	(67.4-241.8)	<u>Testis</u>				
Female	4	4.9	nc	(nc-nc)	Male	4	2.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	2.2	nc	(nc-nc)	Male	8	3.7	217.6	(93.7-428.9)
Female	1	0.7	nc	(nc-nc)	Female	19	12.8	148.9	(89.6-232.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	5.3	nc	(nc-nc)	Female	10	14.2	70.5	(33.7-129.6)
Female	6	4.2	142.4	(52.0-310.0)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	211	192.8	109.4	(95.1-125.2)
Male	5	4.6	107.7	(34.7-251.4)	Female	216	204.6	105.6	(92.0-120.6)
Female	4	1.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	24	24.7	97.1	(62.2-144.4)					
Female	33	27.3	121.0	(83.3-170.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Athol

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	14.2	112.5	(64.3-182.7)	Male	6	8.8	67.9	(24.8-147.8)
Female	6	5.2	114.7	(41.9-249.7)	Female	5	7.0	71.1	(22.9-166.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.6	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
Female	0	2.2	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	7	7.9	88.9	(35.6-183.1)
Female	35	50.2	69.7	(48.5-96.9)	Female	5	6.7	74.6	(24.0-174.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.8	nc	(nc-nc)	Male	12	5.5	218.1	(112.6-381.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	15	16.3	91.9	(51.4-151.6)	Female	7	4.7	148.1	(59.3-305.2)
Female	13	17.3	75.0	(39.9-128.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	4.6	109.9	(35.4-256.4)
Male	7	3.6	194.8	(78.1-401.5)	Female	5	5.2	96.0	(30.9-224.1)
Female	0	1.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	38	50.0	76.1	(53.8-104.4)
Male	4	1.1	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.9	nc	(nc-nc)	Male	1	3.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	2.1	nc	(nc-nc)
Male	6	7.1	84.9	(31.0-184.9)	<u>Testis</u>				
Female	4	4.2	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	2.0	nc	(nc-nc)	Male	0	2.8	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	7	8.7	80.2	(32.1-165.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	5.3	nc	(nc-nc)	Female	16	11.3	141.2	(80.6-229.3)
Female	5	4.0	125.2	(40.3-292.1)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	174	183.0	95.1	(81.5-110.3)
Male	2	4.1	nc	(nc-nc)	Female	157	180.6	86.9	(73.9-101.6)
Female	1	1.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	36	25.0	144.2	(101.0-199.6)					
Female	26	26.0	100.0	(65.3-146.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Attleboro

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	50	39.6	126.3	(93.8-166.6)	Male	29	28.0	103.7	(69.5-149.0)
Female	12	16.2	74.2	(38.3-129.7)	Female	22	24.3	90.6	(56.7-137.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	12	8.6	139.3	(71.9-243.4)	Male	2	7.1	nc	(nc-nc)
Female	6	7.6	78.9	(28.8-171.7)	Female	5	6.2	81.0	(26.1-189.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.3	nc	(nc-nc)	Male	18	24.6	73.1	(43.3-115.5)
Female	159	170.4	93.3	(79.4-109.0)	Female	13	21.6	60.3	(32.1-103.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	6.8	88.3	(32.3-192.3)	Male	24	18.0	133.4	(85.5-198.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	53	48.1	110.2	(82.5-144.1)	Female	23	15.7	146.2	(92.7-219.4)
Female	44	53.6	82.1	(59.6-110.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	7	10.9	64.1	(25.7-132.1)	Male	10	13.0	76.7	(36.7-141.1)
Female	3	3.4	nc	(nc-nc)	Female	11	16.0	68.8	(34.3-123.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	5	4.0	126.2	(40.7-294.5)	Male	153	156.9	97.5	(82.7-114.3)
Female	1	3.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	25	23.2	107.9	(69.8-159.3)	Male	7	9.5	73.6	(29.5-151.7)
Female	14	14.0	100.2	(54.7-168.1)	Female	6	6.5	92.9	(33.9-202.2)
<u>Larynx</u>					<u>Testis</u>				
Male	6	6.4	93.6	(34.2-203.7)	Male	6	6.8	88.3	(32.2-192.2)
Female	3	2.0	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	11	15.5	71.1	(35.4-127.2)	Male	11	10.4	106.2	(52.9-190.0)
Female	12	13.0	92.5	(47.7-161.6)	Female	24	33.1	72.5	(46.4-107.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	17	13.2	129.2	(75.2-206.9)	Female	33	38.4	86.0	(59.2-120.8)
Female	9	4.7	193.1	(88.1-366.5)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	104	74.0	140.6	(114.9-170.4)	Male	584	560.6	104.2	(95.9-113.0)
Female	89	82.8	107.5	(86.3-132.3)	Female	537	595.5	90.2	(82.7-98.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Auburn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	20.2	84.1	(48.9-134.6)	Male	10	12.9	77.8	(37.2-143.1)
Female	8	8.0	100.6	(43.3-198.2)	Female	11	10.7	103.2	(51.5-184.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	3.6	137.7	(44.4-321.4)	Male	3	3.5	nc	(nc-nc)
Female	4	3.3	nc	(nc-nc)	Female	4	3.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	10	11.4	88.1	(42.2-162.0)
Female	66	77.8	84.9	(65.6-108.0)	Female	9	10.2	88.1	(40.2-167.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.8	nc	(nc-nc)	Male	13	7.9	164.0	(87.2-280.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	31	23.2	133.7	(90.8-189.7)	Female	8	7.3	110.3	(47.5-217.4)
Female	23	26.1	88.3	(55.9-132.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	8	6.5	123.3	(53.1-243.0)
Male	5	5.2	96.0	(31.0-224.1)	Female	12	7.9	152.1	(78.5-265.7)
Female	1	1.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	64	73.8	86.7	(66.7-110.7)
Male	2	1.5	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.3	nc	(nc-nc)	Male	8	4.6	172.8	(74.4-340.5)
<u>Kidney & Renal Pelvis</u>					Female	1	3.2	nc	(nc-nc)
Male	14	10.4	134.8	(73.7-226.2)	<u>Testis</u>				
Female	4	6.5	nc	(nc-nc)	Male	5	2.3	219.5	(70.7-512.2)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	3.0	nc	(nc-nc)	Male	3	4.2	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	19	13.2	144.2	(86.8-225.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	10	7.3	136.4	(65.3-250.8)	Female	21	17.8	118.1	(73.0-180.5)
Female	2	6.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	271	265.1	102.2	(90.4-115.2)
Male	5	5.9	84.1	(27.1-196.2)	Female	267	276.9	96.4	(85.2-108.7)
Female	0	2.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	40	36.6	109.1	(78.0-148.6)					
Female	47	40.6	115.9	(85.2-154.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Avon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	5.6	143.3	(61.7-282.3)	Male	2	3.6	nc	(nc-nc)
Female	1	2.0	nc	(nc-nc)	Female	3	2.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.0	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.2	nc	(nc-nc)
Female	20	20.7	96.6	(59.0-149.2)	Female	3	2.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.7	nc	(nc-nc)	Male	4	2.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	6.5	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
Female	4	6.5	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	1.8	nc	(nc-nc)
Male	2	1.5	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	11	21.2	52.0	(25.9-93.0)
Male	1	0.4	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.3	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	0.8	nc	(nc-nc)
Male	6	2.9	206.6	(75.4-449.7)	<u>Testis</u>				
Female	2	1.7	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	0.9	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	5	3.5	142.5	(45.9-332.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	2.0	292.7	(106.9-637.1)	Female	3	4.8	nc	(nc-nc)
Female	2	1.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	80	74.4	107.5	(85.3-133.8)
Male	4	1.7	nc	(nc-nc)	Female	72	72.5	99.3	(77.7-125.0)
Female	0	0.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	10	10.0	99.8	(47.8-183.6)					
Female	15	10.9	138.0	(77.2-227.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ayer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	6.9	nc	(nc-nc)	Male	3	5.1	nc	(nc-nc)
Female	2	2.6	nc	(nc-nc)	Female	6	3.9	153.2	(56.0-333.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.6	nc	(nc-nc)	Male	3	1.3	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	4.5	nc	(nc-nc)
Female	29	27.3	106.1	(71.1-152.4)	Female	5	3.5	144.9	(46.7-338.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.1	nc	(nc-nc)	Male	2	3.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	8.5	nc	(nc-nc)	Female	4	2.5	nc	(nc-nc)
Female	9	8.6	105.2	(48.0-199.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	2.3	nc	(nc-nc)
Male	2	2.0	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	23	28.4	81.0	(51.3-121.5)
Male	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.6	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.0	nc	(nc-nc)
Male	1	4.3	nc	(nc-nc)	<u>Testis</u>				
Female	3	2.2	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	1.2	nc	(nc-nc)	Male	3	2.0	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	4	5.4	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	2.7	nc	(nc-nc)	Female	12	6.1	196.9	(101.6-343.9)
Female	1	2.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	84	100.8	83.3	(66.5-103.2)
Male	1	2.5	nc	(nc-nc)	Female	105	95.4	110.1	(90.0-133.3)
Female	1	0.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	23	12.9	178.3	(113.0-267.5)					
Female	10	13.2	75.6	(36.2-139.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Barnstable

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	89	69.9	127.4	(102.3-156.8)	Male	54	42.4	127.4	(95.7-166.2)
Female	25	24.6	101.7	(65.8-150.1)	Female	44	31.8	138.5	(100.6-185.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	12	11.4	105.4	(54.4-184.1)	Male	11	11.8	93.3	(46.5-167.0)
Female	13	10.0	130.5	(69.4-223.2)	Female	13	9.3	139.8	(74.4-239.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	2.1	nc	(nc-nc)	Male	41	37.3	109.8	(78.8-149.0)
Female	267	235.7	113.3	(100.1-127.7)	Female	36	31.3	115.0	(80.5-159.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	10	8.0	125.0	(59.8-229.9)	Male	21	26.1	80.6	(49.8-123.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	65	78.6	82.7	(63.8-105.4)	Female	22	22.0	100.2	(62.8-151.7)
Female	85	78.9	107.7	(86.0-133.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	19	22.3	85.3	(51.3-133.1)
Male	16	17.7	90.5	(51.7-147.0)	Female	29	24.3	119.4	(79.9-171.4)
Female	2	5.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	335	252.1	132.9	(119.0-147.9)
Male	3	4.3	nc	(nc-nc)	<u>Stomach</u>				
Female	4	3.8	nc	(nc-nc)	Male	17	15.8	107.7	(62.7-172.5)
<u>Kidney & Renal Pelvis</u>					Female	3	9.5	nc	(nc-nc)
Male	34	34.0	99.9	(69.2-139.6)	<u>Testis</u>				
Female	19	20.2	94.1	(56.6-147.0)	Male	9	5.9	153.3	(70.0-291.1)
<u>Larynx</u>					<u>Thyroid</u>				
Male	12	10.1	118.5	(61.2-207.1)	Male	8	12.9	62.2	(26.8-122.5)
Female	3	3.0	nc	(nc-nc)	Female	22	38.1	57.7	(36.1-87.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	33	24.5	134.8	(92.8-189.4)	Female	55	54.7	100.5	(75.7-130.8)
Female	29	18.0	161.2	(107.9-231.5)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	997	893.0	111.6	(104.8-118.8)
Male	18	19.8	90.9	(53.8-143.7)	Female	920	843.9	109.0	(102.1-116.3)
Female	8	6.9	116.2	(50.0-228.9)					
<u>Lung and Bronchus</u>									
Male	116	124.9	92.9	(76.8-111.4)					
Female	137	127.9	107.1	(89.9-126.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Barre

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	6.1	97.6	(35.6-212.4)	Male	2	4.3	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)	Female	0	2.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	1.3	394.1	(127.0-919.7)	Male	0	1.1	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	1	3.7	nc	(nc-nc)
Female	12	20.7	58.1	(30.0-101.4)	Female	2	2.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.8	nc	(nc-nc)	Male	2	2.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	5	7.5	67.0	(21.6-156.3)	Female	1	1.9	nc	(nc-nc)
Female	7	6.3	110.5	(44.3-227.7)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	2	1.8	nc	(nc-nc)	Male	23	27.3	84.4	(53.5-126.6)
Female	1	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.5	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	3.6	165.0	(60.3-359.3)	Female	8	4.6	173.6	(74.7-342.0)
Female	1	1.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	1	1.1	nc	(nc-nc)	Male	4	2.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	3	1.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	0	2.2	nc	(nc-nc)	Male	9	11.8	76.4	(34.9-145.1)
Female	0	0.6	nc	(nc-nc)	Female	8	9.7	82.1	(35.3-161.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Becket

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	2.4	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	12	7.9	152.2	(78.5-265.8)	Female	1	0.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	2.8	nc	(nc-nc)	Female	3	0.7	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.7	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	6	10.8	55.6	(20.3-120.9)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	1	1.4	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	0.8	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.8	nc	(nc-nc)	Female	6	1.9	319.5	(116.7-695.4)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	7	4.6	151.2	(60.6-311.5)	Male	23	34.4	66.8	(42.3-100.2)
Female	2	3.7	nc	(nc-nc)	Female	33	26.3	125.6	(86.4-176.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bedford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	22.2	76.7	(44.6-122.8)	Male	17	12.8	133.1	(77.5-213.2)
Female	3	5.9	nc	(nc-nc)	Female	6	8.0	75.1	(27.4-163.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	3.5	nc	(nc-nc)	Male	0	3.6	nc	(nc-nc)
Female	0	2.5	nc	(nc-nc)	Female	2	2.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	11	11.6	95.0	(47.3-169.9)
Female	59	59.2	99.7	(75.9-128.6)	Female	6	7.6	78.8	(28.8-171.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.1	nc	(nc-nc)	Male	9	7.5	119.4	(54.5-226.8)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	19	24.5	77.5	(46.6-121.0)	Female	5	5.5	91.3	(29.4-213.0)
Female	21	19.4	108.4	(67.1-165.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	8	6.9	116.7	(50.3-230.0)
Male	4	5.2	nc	(nc-nc)	Female	6	5.8	102.6	(37.5-223.3)
Female	3	1.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	64	71.2	89.8	(69.2-114.7)
Male	0	1.2	nc	(nc-nc)	<u>Stomach</u>				
Female	2	0.9	nc	(nc-nc)	Male	3	4.9	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	2.3	nc	(nc-nc)
Male	8	10.1	79.0	(34.0-155.7)	<u>Testis</u>				
Female	6	4.9	122.0	(44.5-265.5)	Male	2	1.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	3.0	nc	(nc-nc)	Male	3	3.7	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	5	10.0	50.0	(16.1-116.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	9	7.8	115.6	(52.7-219.5)	Female	18	13.5	133.4	(79.0-210.8)
Female	5	4.5	111.7	(36.0-260.7)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	226	268.2	84.3	(73.6-96.0)
Male	4	5.8	nc	(nc-nc)	Female	198	208.0	95.2	(82.4-109.4)
Female	0	1.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	26	38.3	67.9	(44.4-99.5)					
Female	28	30.1	93.0	(61.8-134.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Belchertown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	12.2	89.9	(44.8-160.9)	Male	7	8.8	79.5	(31.8-163.7)
Female	5	4.3	116.5	(37.5-271.9)	Female	7	7.5	93.3	(37.4-192.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.8	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	12	7.8	153.5	(79.2-268.1)
Female	49	54.0	90.7	(67.1-119.9)	Female	2	6.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.2	nc	(nc-nc)	Male	7	6.1	115.2	(46.1-237.3)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	17	15.3	110.9	(64.6-177.5)	Female	3	4.8	nc	(nc-nc)
Female	12	14.3	83.8	(43.3-146.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	4.1	nc	(nc-nc)
Male	3	3.5	nc	(nc-nc)	Female	3	4.2	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	55	50.1	109.8	(82.7-142.9)
Male	1	1.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1.0	nc	(nc-nc)	Male	5	3.0	165.3	(53.3-385.8)
<u>Kidney & Renal Pelvis</u>					Female	2	1.7	nc	(nc-nc)
Male	6	7.4	80.7	(29.5-175.8)	<u>Testis</u>				
Female	2	4.2	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	2.0	nc	(nc-nc)	Male	1	3.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	5	11.2	44.8	(14.4-104.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	5.0	nc	(nc-nc)	Female	10	12.3	81.4	(39.0-149.7)
Female	1	3.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	166	177.2	93.7	(80.0-109.1)
Male	5	4.3	116.8	(37.6-272.6)	Female	142	177.1	80.2	(67.5-94.5)
Female	1	1.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	17	22.3	76.1	(44.3-121.9)					
Female	22	23.3	94.6	(59.3-143.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bellingham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	14.6	75.5	(37.7-135.2)	Male	4	10.1	nc	(nc-nc)
Female	10	5.1	197.5	(94.5-363.2)	Female	9	8.5	106.0	(48.4-201.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	3.1	222.9	(89.3-459.4)	Male	0	2.6	nc	(nc-nc)
Female	1	2.6	nc	(nc-nc)	Female	3	2.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	12	8.9	134.4	(69.4-234.8)
Female	71	61.5	115.5	(90.2-145.6)	Female	10	7.1	140.3	(67.2-258.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	2.5	nc	(nc-nc)	Male	9	6.6	135.5	(61.9-257.3)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	16	17.8	89.7	(51.2-145.6)	Female	2	5.5	nc	(nc-nc)
Female	15	16.6	90.4	(50.5-149.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	4.9	nc	(nc-nc)
Male	5	4.0	123.8	(39.9-289.0)	Female	3	4.9	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	74	58.6	126.2	(99.1-158.5)
Male	1	1.4	nc	(nc-nc)	<u>Stomach</u>				
Female	2	1.2	nc	(nc-nc)	Male	2	3.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	1.9	nc	(nc-nc)
Male	8	8.4	95.0	(40.9-187.2)	<u>Testis</u>				
Female	4	4.9	nc	(nc-nc)	Male	3	2.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	2.3	nc	(nc-nc)	Male	4	3.7	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	10	12.4	80.8	(38.7-148.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	5.8	86.3	(27.8-201.4)	Female	14	14.0	99.7	(54.5-167.4)
Female	1	4.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	215	206.4	104.2	(90.7-119.1)
Male	5	4.7	106.1	(34.2-247.7)	Female	219	204.1	107.3	(93.6-122.5)
Female	0	1.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	30	26.7	112.3	(75.8-160.4)					
Female	33	27.8	118.7	(81.7-166.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Belmont

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	26	27.3	95.2	(62.2-139.5)	Male	19	17.5	108.4	(65.2-169.3)
Female	8	11.0	72.9	(31.4-143.7)	Female	17	15.3	110.9	(64.6-177.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	5.0	119.5	(43.6-260.1)	Male	4	4.7	nc	(nc-nc)
Female	7	4.8	146.4	(58.6-301.6)	Female	2	4.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.8	nc	(nc-nc)	Male	17	15.4	110.2	(64.2-176.5)
Female	131	111.5	117.5	(98.2-139.4)	Female	9	14.3	62.9	(28.7-119.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	4.1	nc	(nc-nc)	Male	6	11.1	54.0	(19.7-117.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	22	31.5	69.9	(43.8-105.9)	Female	15	10.3	145.8	(81.5-240.4)
Female	29	36.2	80.2	(53.7-115.1)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	4	7.2	nc	(nc-nc)	Male	111	104.1	106.6	(87.7-128.3)
Female	1	2.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	2	2.0	nc	(nc-nc)	Male	1	3.0	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	12	14.4	83.4	(43.1-145.8)	Female	22	25.3	87.1	(54.6-131.9)
Female	4	9.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	1	4.2	nc	(nc-nc)	Male	5	10.1	49.4	(15.9-115.2)
Female	1	1.3	nc	(nc-nc)	Female	1	8.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	2	8.2	nc	(nc-nc)	Male	34	49.4	68.8	(47.6-96.1)
Female	4	3.1	nc	(nc-nc)	Female	39	56.0	69.7	(49.6-95.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Berkley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	4.9	nc	(nc-nc)	Male	2	3.8	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	2	3.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.2	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	6	3.3	180.7	(66.0-393.3)
Female	31	20.8	148.7	(101.0-211.1)	Female	1	2.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.0	nc	(nc-nc)	Male	3	2.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	6.4	nc	(nc-nc)	Female	0	1.8	nc	(nc-nc)
Female	5	5.1	98.4	(31.7-229.7)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	1	1.5	nc	(nc-nc)	Male	15	22.3	67.3	(37.6-111.0)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	1	0.5	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	3.3	153.0	(49.3-357.1)	Female	5	4.6	109.1	(35.1-254.5)
Female	2	1.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	1	0.9	nc	(nc-nc)	Male	0	2.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	3	1.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	0	1.9	nc	(nc-nc)	Male	5	9.5	52.5	(16.9-122.6)
Female	1	0.5	nc	(nc-nc)	Female	8	8.2	97.5	(42.0-192.1)
<u>Female</u>					<u>Male</u>				
					73.6 (55.6-95.6)				
					120.2 (95.3-149.6)				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Berlin

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	4.9	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
Female	4	1.1	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.8	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	2.6	nc	(nc-nc)
Female	7	12.6	55.7	(22.3-114.7)	Female	1	1.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	5.4	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
Female	3	3.6	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	1	1.3	nc	(nc-nc)	Male	12	18.7	64.2	(33.1-112.2)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	2.4	nc	(nc-nc)	Female	4	2.9	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	0	0.7	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	0	1.4	nc	(nc-nc)	Male	8	8.9	89.6	(38.6-176.5)
Female	0	0.3	nc	(nc-nc)	Female	8	6.1	131.5	(56.6-259.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bernardston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	3.3	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	4	1.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
Female	7	10.5	66.7	(26.7-137.5)	Female	2	1.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	3.9	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
Female	5	3.2	155.2	(50.0-362.2)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	2	0.9	nc	(nc-nc)	Male	17	12.9	131.4	(76.5-210.4)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	1	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	1.8	nc	(nc-nc)	Female	1	2.5	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	0	0.5	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	0	1.0	nc	(nc-nc)	Male	3	6.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	5.2	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Beverly

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	46	48.7	94.5	(69.1-126.0)	Male	25	30.6	81.8	(52.9-120.7)
Female	21	17.5	120.3	(74.5-183.9)	Female	33	24.3	135.8	(93.4-190.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	8.7	68.7	(25.1-149.6)	Male	7	8.3	84.3	(33.8-173.7)
Female	9	7.6	118.3	(54.0-224.7)	Female	5	6.6	75.7	(24.4-176.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.5	nc	(nc-nc)	Male	36	27.3	132.1	(92.5-182.9)
Female	157	172.1	91.2	(77.5-106.6)	Female	19	22.6	84.0	(50.6-131.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	6.4	nc	(nc-nc)	Male	23	18.9	121.9	(77.2-182.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	32	55.9	57.2	(39.1-80.8)	Female	16	16.1	99.2	(56.7-161.1)
Female	52	57.8	90.0	(67.2-118.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	17	12.4	137.2	(79.9-219.7)	Male	9	15.5	58.0	(26.5-110.2)
Female	2	3.6	nc	(nc-nc)	Female	11	17.3	63.5	(31.6-113.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	3.7	nc	(nc-nc)	Male	170	175.1	97.1	(83.0-112.8)
Female	3	3.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	27	24.6	109.9	(72.4-159.9)	Male	7	11.2	62.5	(25.0-128.7)
Female	16	14.4	111.4	(63.6-180.9)	Female	3	7.0	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	5	7.1	70.1	(22.6-163.6)	Male	7	5.6	124.2	(49.8-256.0)
Female	3	2.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	19	17.8	106.5	(64.1-166.3)	Male	8	9.9	80.5	(34.7-158.7)
Female	9	13.4	66.9	(30.5-127.1)	Female	34	30.9	110.0	(76.2-153.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	14	14.1	98.9	(54.0-166.0)	Female	31	39.0	79.6	(54.1-113.0)
Female	12	4.9	244.1	(126.0-426.4)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	82	86.6	94.7	(75.3-117.6)	Male	602	633.5	95.0	(87.6-102.9)
Female	95	87.6	108.4	(87.7-132.5)	Female	609	613.9	99.2	(91.5-107.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Billerica

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	46	36.0	127.8	(93.5-170.4)	Male	35	25.7	136.3	(94.9-189.5)
Female	19	12.2	155.2	(93.4-242.3)	Female	19	20.6	92.4	(55.6-144.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	7.8	127.6	(61.1-234.6)	Male	7	6.6	106.2	(42.6-218.9)
Female	7	6.4	109.7	(44.0-226.1)	Female	5	4.8	103.4	(33.3-241.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.2	nc	(nc-nc)	Male	16	22.5	71.2	(40.7-115.7)
Female	124	148.8	83.3	(69.3-99.3)	Female	18	17.3	104.3	(61.8-164.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	6.0	nc	(nc-nc)	Male	15	17.0	88.3	(49.4-145.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	45	44.6	100.9	(73.6-135.1)	Female	15	13.4	112.3	(62.8-185.2)
Female	40	40.1	99.7	(71.2-135.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	14	12.0	116.4	(63.6-195.3)
Male	10	10.3	96.8	(46.4-178.1)	Female	11	11.9	92.2	(45.9-164.9)
Female	3	2.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	121	153.3	78.9	(65.5-94.3)
Male	2	3.5	nc	(nc-nc)	<u>Stomach</u>				
Female	2	2.8	nc	(nc-nc)	Male	12	8.8	136.0	(70.2-237.6)
<u>Kidney & Renal Pelvis</u>					Female	2	4.7	nc	(nc-nc)
Male	25	21.5	116.2	(75.2-171.5)	<u>Testis</u>				
Female	12	11.8	102.1	(52.7-178.3)	Male	10	5.9	170.2	(81.5-313.0)
<u>Larynx</u>					<u>Thyroid</u>				
Male	5	6.1	82.6	(26.6-192.8)	Male	10	9.5	104.8	(50.2-192.7)
Female	1	1.8	nc	(nc-nc)	Female	26	29.9	86.9	(56.8-127.3)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	27	14.3	189.3	(124.7-275.4)	Female	30	34.4	87.1	(58.8-124.4)
Female	18	10.2	176.8	(104.8-279.5)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	557	524.8	106.1	(97.5-115.3)
Male	13	12.2	106.2	(56.5-181.7)	Female	484	493.7	98.0	(89.5-107.2)
Female	3	3.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	86	67.6	127.1	(101.7-157.0)					
Female	83	66.8	124.3	(99.0-154.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Blackstone

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	9.6	104.3	(49.9-191.9)	Male	4	6.8	nc	(nc-nc)
Female	3	2.9	nc	(nc-nc)	Female	4	4.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.1	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	Female	3	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	5	5.9	84.7	(27.3-197.6)
Female	31	33.5	92.5	(62.8-131.2)	Female	4	4.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.4	nc	(nc-nc)	Male	2	4.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	7	11.6	60.3	(24.2-124.2)	Female	2	3.0	nc	(nc-nc)
Female	4	9.6	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	3.2	nc	(nc-nc)
Male	5	2.8	181.6	(58.5-423.7)	Female	3	2.8	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	40	40.8	98.1	(70.1-133.6)
Male	2	0.9	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.7	nc	(nc-nc)	Male	3	2.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.1	nc	(nc-nc)
Male	4	5.6	nc	(nc-nc)	<u>Testis</u>				
Female	5	2.7	186.8	(60.2-435.9)	Male	0	1.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	1.6	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	4	6.8	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	3.8	nc	(nc-nc)	Female	10	7.5	132.5	(63.4-243.7)
Female	1	2.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	128	138.6	92.4	(77.1-109.8)
Male	4	3.3	nc	(nc-nc)	Female	102	113.3	90.0	(73.4-109.2)
Female	0	0.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	24	18.0	133.3	(85.4-198.4)					
Female	17	15.4	110.5	(64.4-177.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Blandford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.0	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	6	5.2	115.7	(42.3-251.9)	Female	1	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	1.3	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	8	4.8	165.9	(71.4-327.0)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	0.2	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.4	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.4	nc	(nc-nc)	Female	3	1.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	19	15.8	120.0	(72.2-187.3)
Male	0	0.4	nc	(nc-nc)	Female	20	16.7	119.5	(73.0-184.6)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	3	1.9	nc	(nc-nc)					
Female	1	2.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bolton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	3.7	136.9	(44.1-319.5)	Male	4	2.7	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	1	2.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	0.9	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
Female	18	17.3	104.1	(61.7-164.6)	Female	1	1.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	4	1.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	5	4.7	106.0	(34.2-247.4)	Female	3	1.5	nc	(nc-nc)
Female	0	4.1	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	1.1	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	0	0.4	nc	(nc-nc)	Female	24	15.4	155.8	(99.8-231.8)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	0	2.4	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	1	0.6	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	2	1.5	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	1	1.4	nc	(nc-nc)	Female	12	3.9	307.6	(158.8-537.3)
Female	0	0.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	6	7.0	85.4	(31.2-185.9)	Female	61	54.5	111.8	(85.5-143.7)
Female	5	6.6	75.4	(24.3-175.9)	Female	49	53.9	90.8	(67.2-120.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Boston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	350	477.9	73.2	(65.8-81.3)	Male	261	339.9	76.8	(67.8-86.7)
Female	126	179.2	70.3	(58.6-83.7)	Female	253	297.0	85.2	(75.0-96.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	84	109.2	76.9	(61.4-95.2)	Male	101	83.9	120.4	(98.1-146.3)
Female	94	92.9	101.2	(81.8-123.9)	Female	92	68.4	134.4	(108.4-164.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	8	14.8	54.0	(23.3-106.5)	Male	301	298.0	101.0	(89.9-113.1)
Female	1766	1908.0	92.6	(88.3-97.0)	Female	227	245.9	92.3	(80.7-105.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	97	83.3	116.5	(94.5-142.1)	Male	221	208.8	105.8	(92.3-120.7)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	621	572.6	108.5	(100.1-117.3)	Female	173	179.9	96.1	(82.4-111.6)
Female	644	590.8	109.0	(100.8-117.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	143	156.1	91.6	(77.2-107.9)
Male	99	128.4	77.1	(62.6-93.8)	Female	199	176.6	112.7	(97.6-129.5)
Female	52	37.4	139.1	(103.8-182.4)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	1932	1840.3	105.0	(100.4-109.8)
Male	50	62.0	80.7	(59.9-106.4)	<u>Stomach</u>				
Female	67	50.9	131.6	(102.0-167.2)	Male	131	113.9	115.1	(96.2-136.5)
<u>Kidney & Renal Pelvis</u>					Female	106	71.1	149.1	(122.0-180.3)
Male	255	268.5	95.0	(83.7-107.4)	<u>Testis</u>				
Female	205	158.9	129.0	(111.9-147.9)	Male	94	115.9	81.1	(65.6-99.3)
<u>Larynx</u>					<u>Thyroid</u>				
Male	86	74.3	115.7	(92.5-142.9)	Male	134	128.9	103.9	(87.1-123.1)
Female	22	23.0	95.5	(59.8-144.6)	Female	514	425.4	120.8	(110.6-131.7)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	143	194.1	73.7	(62.1-86.8)	Female	448	431.6	103.8	(94.4-113.9)
Female	127	150.3	84.5	(70.4-100.5)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	6700	6724.3	99.6	(97.3-102.1)
Male	260	151.3	171.9	(151.6-194.1)	Female	6755	6786.1	99.5	(97.2-101.9)
Female	86	52.1	165.1	(132.1-204.0)					
<u>Lung and Bronchus</u>									
Male	896	867.8	103.2	(96.6-110.2)					
Female	844	931.1	90.6	(84.6-97.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bourne

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	27	26.3	102.8	(67.7-149.5)	Male	23	16.0	143.3	(90.8-215.1)
Female	14	9.4	149.3	(81.6-250.6)	Female	13	12.3	105.9	(56.3-181.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	4.5	133.2	(48.6-289.9)	Male	5	4.4	112.7	(36.3-263.0)
Female	5	3.9	129.1	(41.6-301.3)	Female	7	3.5	197.3	(79.1-406.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	16	14.3	111.8	(63.9-181.6)
Female	99	89.7	110.3	(89.7-134.3)	Female	9	12.0	75.1	(34.3-142.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	3.1	nc	(nc-nc)	Male	13	9.7	134.0	(71.3-229.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	28	29.3	95.4	(63.4-138.0)	Female	12	8.4	142.4	(73.5-248.7)
Female	22	30.2	72.8	(45.6-110.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	7	8.3	84.3	(33.8-173.6)
Male	7	6.6	106.4	(42.6-219.2)	Female	11	9.3	118.5	(59.1-212.1)
Female	6	2.0	303.5	(110.8-660.7)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	119	93.1	127.9	(105.9-153.0)
Male	2	1.9	nc	(nc-nc)	<u>Stomach</u>				
Female	2	1.5	nc	(nc-nc)	Male	6	5.9	101.4	(37.0-220.7)
<u>Kidney & Renal Pelvis</u>					Female	3	3.6	nc	(nc-nc)
Male	12	12.9	93.1	(48.0-162.6)	<u>Testis</u>				
Female	6	7.7	78.0	(28.5-169.7)	Male	1	2.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	3.8	nc	(nc-nc)	Male	0	5.0	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	16	14.8	108.0	(61.7-175.3)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	12	9.4	127.8	(66.0-223.3)	Female	15	20.9	71.7	(40.1-118.3)
Female	8	7.0	115.1	(49.5-226.7)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	380	335.6	113.2	(102.1-125.2)
Male	6	7.4	80.9	(29.5-176.0)	Female	341	322.6	105.7	(94.8-117.5)
Female	0	2.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	52	47.0	110.6	(82.6-145.0)					
Female	64	48.5	131.9	(101.6-168.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Boxborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	3.9	nc	(nc-nc)	Male	8	3.0	264.9	(114.1-522.0)
Female	1	1.1	nc	(nc-nc)	Female	4	2.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.0	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
Female	25	17.3	144.1	(93.2-212.7)	Female	5	1.8	285.3	(91.9-665.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	5.0	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
Female	7	3.9	179.3	(71.8-369.3)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	1.2	nc	(nc-nc)	Male	27	18.2	148.7	(97.9-216.3)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	1	0.4	nc	(nc-nc)	Male	3	0.7	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	2.6	nc	(nc-nc)	Female	7	3.9	180.1	(72.1-371.1)
Female	0	1.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	1	0.7	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	0	1.5	nc	(nc-nc)	Male	1	7.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	6	6.4	93.4	(34.1-203.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Boxford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	9.2	87.0	(37.5-171.4)	Male	19	6.1	309.0	(185.9-482.5)
Female	0	2.6	nc	(nc-nc)	Female	7	4.3	163.4	(65.4-336.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.8	nc	(nc-nc)	Male	4	1.6	nc	(nc-nc)
Female	3	1.3	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	2	5.4	nc	(nc-nc)
Female	46	32.9	140.0	(102.5-186.8)	Female	2	3.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.3	nc	(nc-nc)	Male	3	4.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	10	11.1	90.1	(43.1-165.6)	Female	2	2.9	nc	(nc-nc)
Female	3	8.5	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	3.0	nc	(nc-nc)
Male	1	2.5	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	54	36.1	149.7	(112.4-195.3)
Male	1	0.7	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.5	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.0	nc	(nc-nc)
Male	4	5.1	nc	(nc-nc)	<u>Testis</u>				
Female	4	2.5	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.5	nc	(nc-nc)	Male	3	2.1	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	8	6.2	128.6	(55.4-253.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	10	3.5	288.5	(138.1-530.6)	Female	6	7.5	79.9	(29.2-173.8)
Female	4	2.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	143	126.8	112.8	(95.1-132.9)
Male	3	3.0	nc	(nc-nc)	Female	112	105.4	106.2	(87.5-127.8)
Female	0	0.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	5	17.0	29.4	(9.5-68.6)					
Female	12	14.0	85.9	(44.4-150.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Boylston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	4.1	123.3	(39.7-287.7)	Male	2	2.9	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	3	2.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.9	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
Female	22	18.5	118.9	(74.5-180.1)	Female	0	2.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.7	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	5.2	nc	(nc-nc)	Female	3	1.6	nc	(nc-nc)
Female	9	5.1	176.1	(80.4-334.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	1.4	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	22	16.7	131.5	(82.4-199.1)
Male	1	0.4	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.3	nc	(nc-nc)	Male	3	1.0	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.6	nc	(nc-nc)
Male	2	2.5	nc	(nc-nc)	<u>Testis</u>				
Female	2	1.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	0.7	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	4	3.5	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.6	nc	(nc-nc)	Female	3	4.3	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	57	59.1	96.4	(73.0-124.9)
Male	1	1.4	nc	(nc-nc)	Female	58	61.4	94.4	(71.7-122.0)
Female	0	0.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	4	7.5	nc	(nc-nc)					
Female	6	8.5	70.9	(25.9-154.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Braintree

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	52	40.1	129.8	(96.9-170.2)	Male	34	25.5	133.4	(92.4-186.4)
Female	20	17.0	117.8	(71.9-182.0)	Female	33	22.6	146.1	(100.5-205.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	7.3	136.4	(65.3-250.8)	Male	8	6.8	117.1	(50.4-230.8)
Female	10	7.1	140.5	(67.3-258.4)	Female	9	6.4	140.4	(64.1-266.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.2	nc	(nc-nc)	Male	23	22.5	102.1	(64.7-153.2)
Female	163	164.3	99.2	(84.6-115.7)	Female	20	21.7	92.0	(56.1-142.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	5.9	102.5	(37.4-223.0)	Male	18	15.8	114.0	(67.6-180.3)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	53	45.8	115.8	(86.8-151.5)	Female	18	15.3	117.5	(69.6-185.6)
Female	66	55.3	119.3	(92.3-151.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	6	12.9	46.5	(17.0-101.3)
Male	16	10.4	153.3	(87.6-249.0)	Female	17	16.8	101.0	(58.8-161.7)
Female	3	3.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	149	149.5	99.7	(84.3-117.0)
Male	2	2.9	nc	(nc-nc)	<u>Stomach</u>				
Female	1	2.8	nc	(nc-nc)	Male	16	9.2	173.8	(99.3-282.3)
<u>Kidney & Renal Pelvis</u>					Female	9	6.7	134.2	(61.2-254.7)
Male	21	20.8	100.8	(62.4-154.1)	<u>Testis</u>				
Female	16	13.9	114.9	(65.6-186.6)	Male	5	4.4	114.8	(37.0-268.0)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	6.0	nc	(nc-nc)	Male	8	8.3	96.3	(41.5-189.8)
Female	4	2.0	nc	(nc-nc)	Female	38	27.9	136.2	(96.3-186.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	15	14.7	102.3	(57.2-168.7)	Female	42	37.5	112.0	(80.7-151.4)
Female	11	12.8	86.0	(42.9-153.9)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	597	529.5	112.7	(103.9-122.2)
Male	15	11.8	127.2	(71.2-209.9)	Female	659	587.8	112.1	(103.7-121.0)
Female	4	4.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	84	73.3	114.6	(91.4-141.9)					
Female	107	86.7	123.4	(101.1-149.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brewster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	21.3	75.1	(42.9-121.9)	Male	20	11.9	168.6	(102.9-260.4)
Female	7	7.1	98.6	(39.5-203.3)	Female	21	8.1	258.3	(159.8-394.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.0	nc	(nc-nc)	Male	2	3.4	nc	(nc-nc)
Female	1	2.6	nc	(nc-nc)	Female	2	2.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	11	10.6	103.8	(51.7-185.7)
Female	67	61.1	109.6	(85.0-139.2)	Female	10	8.6	115.6	(55.4-212.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.9	nc	(nc-nc)	Male	11	6.9	158.6	(79.1-283.8)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	19	22.7	83.7	(50.4-130.8)	Female	1	5.9	nc	(nc-nc)
Female	16	23.0	69.6	(39.7-113.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	4	5.1	nc	(nc-nc)	Male	6	6.6	91.2	(33.3-198.6)
Female	2	1.5	nc	(nc-nc)	Female	7	7.1	98.9	(39.6-203.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.9	nc	(nc-nc)	Male	80	71.1	112.5	(89.2-140.0)
Female	0	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	9	9.4	95.8	(43.7-182.0)	Male	3	4.7	nc	(nc-nc)
Female	3	5.4	nc	(nc-nc)	Female	1	2.8	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	1	2.9	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	4	7.0	nc	(nc-nc)	Male	1	3.1	nc	(nc-nc)
Female	3	5.0	nc	(nc-nc)	Female	5	8.6	58.3	(18.8-136.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	5.5	nc	(nc-nc)	Female	18	14.2	126.9	(75.2-200.6)
Female	0	1.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	26	37.5	69.3	(45.2-101.5)	Male	241	255.6	94.3	(82.7-107.0)
Female	16	35.0	45.7	(26.1-74.2)	Female	199	226.9	87.7	(76.0-100.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	22	24.3	90.4	(56.6-136.8)	Male	18	18.0	100.0	(59.2-158.0)
Female	9	7.1	127.2	(58.1-241.5)	Female	12	11.9	101.0	(52.1-176.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	5.7	106.1	(38.8-231.0)	Male	4	4.4	nc	(nc-nc)
Female	6	3.7	160.2	(58.5-348.6)	Female	4	2.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.8	nc	(nc-nc)	Male	11	15.7	70.1	(35.0-125.5)
Female	89	82.3	108.2	(86.9-133.1)	Female	10	9.9	101.0	(48.4-185.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	3.3	150.2	(48.4-350.6)	Male	9	12.0	75.1	(34.3-142.6)
<u>Colon / Rectum</u>					Female	10	4.0	247.3	(118.4-454.9)
Male	23	30.0	76.7	(48.6-115.1)	<u>Ovary</u>				
Female	30	23.4	128.4	(86.6-183.4)	Female	8	7.5	106.5	(45.8-209.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	7.1	98.7	(39.6-203.5)	Male	7	8.2	85.1	(34.1-175.4)
Female	2	1.5	nc	(nc-nc)	Female	7	6.9	101.1	(40.5-208.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	2.8	nc	(nc-nc)	Male	92	104.5	88.1	(71.0-108.0)
Female	2	2.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	6.0	nc	(nc-nc)
Male	13	15.2	85.6	(45.6-146.4)	Female	4	2.7	nc	(nc-nc)
Female	5	6.6	75.8	(24.4-177.0)	<u>Testis</u>				
<u>Larynx</u>					Male	4	4.7	nc	(nc-nc)
Male	2	4.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.0	nc	(nc-nc)	Male	9	7.0	129.0	(58.8-244.8)
<u>Leukemia</u>					Female	17	17.0	100.0	(58.2-160.2)
Male	8	9.8	81.8	(35.2-161.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	6.0	nc	(nc-nc)	Female	16	18.7	85.6	(48.9-138.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	11	8.5	129.8	(64.7-232.3)	Male	325	360.9	90.0	(80.5-100.4)
Female	3	2.1	nc	(nc-nc)	Female	308	279.3	110.3	(98.3-123.3)
<u>Lung and Bronchus</u>									
Male	48	46.3	103.6	(76.4-137.4)					
Female	44	37.9	116.2	(84.4-155.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brimfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	3.4	nc	(nc-nc)	Male	0	2.6	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.8	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
Female	13	15.1	86.2	(45.8-147.4)	Female	1	1.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.6	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	6	4.2	142.0	(51.8-309.1)	Female	0	1.4	nc	(nc-nc)
Female	5	4.2	117.8	(38.0-275.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	1	1.1	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female				
<u>Hodgkin Lymphoma</u>					Male				
Male	0	0.3	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
Female	2	0.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	5	2.3	217.9	(70.2-508.5)	Female	13	17.3	75.0	(39.9-128.2)
Female	1	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Larynx</u>					Male				
Male	1	0.7	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Leukemia</u>					Male				
Male	0	1.3	nc	(nc-nc)	Female	2	0.5	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	<u>Thyroid</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male				
Male	1	1.4	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female				
<u>Lung and Bronchus</u>					Uteri Corpus and Uterus, NOS				
Male	7	6.6	105.5	(42.2-217.3)	Female	4	3.5	nc	(nc-nc)
Female	13	6.8	190.1	(101.1-325.2)	<u>All Sites / Types</u>				
					Male				
					Female				
					Male	48	54.0	88.8	(65.5-117.8)
					Female	56	50.2	111.5	(84.2-144.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brockton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	77	79.9	96.4	(76.1-120.5)	Male	40	55.8	71.7	(51.2-97.7)
Female	26	32.1	80.9	(52.8-118.6)	Female	26	50.6	51.4	(33.5-75.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	13	17.6	73.9	(39.3-126.3)	Male	14	14.2	98.3	(53.7-165.0)
Female	10	16.2	61.7	(29.5-113.4)	Female	18	12.4	145.4	(86.1-229.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	2.5	nc	(nc-nc)	Male	44	49.2	89.4	(65.0-120.1)
Female	291	351.3	82.8	(73.6-92.9)	Female	54	43.8	123.4	(92.7-161.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	21	14.2	147.8	(91.4-225.9)	Male	46	36.1	127.4	(93.3-170.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	118	96.9	121.8	(100.8-145.8)	Female	35	32.4	108.0	(75.2-150.2)
Female	115	105.8	108.7	(89.7-130.4)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	30	22.0	136.1	(91.8-194.4)	Male	316	318.4	99.3	(88.6-110.8)
Female	10	6.7	149.1	(71.4-274.3)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	6	8.1	74.2	(27.1-161.4)	Male	9	13.5	66.5	(30.3-126.2)
Female	10	7.5	134.0	(64.2-246.5)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	50	45.9	108.9	(80.8-143.6)	Female	77	80.1	96.2	(75.9-120.2)
Female	34	28.7	118.3	(81.9-165.4)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	19	12.8	148.6	(89.4-232.1)	Male	1203	1129.6	106.5	(100.6-112.7)
Female	4	4.2	nc	(nc-nc)	Female	1234	1218.0	101.3	(95.7-107.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	29	32.1	90.3	(60.4-129.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	21	26.7	78.5	(48.6-120.0)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	33	26.3	125.7	(86.5-176.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	15	9.5	158.5	(88.7-261.5)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Lung and Bronchus</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	184	147.4	124.8	(107.5-144.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	192	168.0	114.3	(98.7-131.6)	<u>Uteri Corpus and Uterus, NOS</u>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	3.9	203.8	(87.7-401.5)	Male	3	2.8	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.8	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.1	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
Female	16	14.2	112.6	(64.3-182.9)	Female	1	1.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	5	4.8	103.3	(33.3-241.1)	Female	2	1.3	nc	(nc-nc)
Female	4	4.2	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	1.4	nc	(nc-nc)
Male	2	1.3	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	10	19.9	50.3	(24.1-92.6)
Male	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.5	nc	(nc-nc)
Male	1	2.4	nc	(nc-nc)	<u>Testis</u>				
Female	0	1.2	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	0.7	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	2.6	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.5	nc	(nc-nc)	Female	7	3.3	211.2	(84.6-435.2)
Female	0	1.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	48	60.7	79.1	(58.3-104.8)
Male	1	1.5	nc	(nc-nc)	Female	51	48.6	105.0	(78.2-138.1)
Female	2	0.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	8	7.8	103.1	(44.4-203.1)					
Female	5	7.1	70.8	(22.8-165.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brookline

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	54	55.9	96.6	(72.6-126.0)	Male	48	37.2	129.2	(95.3-171.3)
Female	19	21.4	88.9	(53.5-138.8)	Female	60	33.6	178.8	(136.4-230.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	22	10.9	202.8	(127.0-307.0)	Male	10	9.7	103.5	(49.6-190.4)
Female	10	10.3	97.4	(46.6-179.1)	Female	11	8.1	135.1	(67.3-241.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.7	nc	(nc-nc)	Male	39	32.4	120.2	(85.5-164.4)
Female	258	221.4	116.5	(102.7-131.7)	Female	30	28.7	104.6	(70.6-149.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	9.2	nc	(nc-nc)	Male	13	23.3	55.8	(29.7-95.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	49	64.8	75.6	(55.9-99.9)	Female	19	21.0	90.4	(54.4-141.2)
Female	59	71.0	83.1	(63.3-107.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	21	18.2	115.6	(71.5-176.7)
Male	8	15.1	53.1	(22.9-104.7)	Female	22	21.2	104.0	(65.2-157.5)
Female	5	4.4	113.3	(36.5-264.4)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	213	218.7	97.4	(84.8-111.4)
Male	7	5.2	135.9	(54.4-280.0)	<u>Stomach</u>				
Female	5	5.2	95.9	(30.9-223.9)	Male	9	13.1	68.9	(31.5-130.9)
<u>Kidney & Renal Pelvis</u>					Female	11	8.6	128.1	(63.9-229.3)
Male	30	29.9	100.2	(67.6-143.0)	<u>Testis</u>				
Female	19	18.3	103.7	(62.4-162.0)	Male	14	8.8	159.8	(87.3-268.2)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	8.7	nc	(nc-nc)	Male	22	12.8	172.4	(108.0-261.0)
Female	0	2.7	nc	(nc-nc)	Female	58	46.4	125.0	(94.9-161.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	34	20.9	162.4	(112.4-226.9)	Female	47	50.7	92.8	(68.1-123.3)
Female	24	17.2	139.9	(89.6-208.1)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	712	764.0	93.2	(86.5-100.3)
Male	4	17.2	nc	(nc-nc)	Female	812	788.0	103.0	(96.1-110.4)
Female	7	6.1	114.3	(45.8-235.6)					
<u>Lung and Bronchus</u>									
Male	72	102.2	70.5	(55.1-88.7)					
Female	82	108.1	75.9	(60.3-94.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Buckland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	3.9	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	10	9.0	111.3	(53.3-204.7)	Female	1	1.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	4.2	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	2	2.6	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	1	0.9	nc	(nc-nc)	Male	8	12.4	64.8	(27.9-127.6)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	1.7	nc	(nc-nc)	Female	0	2.1	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Male</u>				
Male	1	0.5	nc	(nc-nc)	24	46.3	51.8	(33.2-77.1)	
Female	0	0.1	nc	(nc-nc)	<u>Female</u>				
<u>Leukemia</u>					27				
Male	0	1.3	nc	(nc-nc)	30.6	88.2	(58.1-128.4)		
Female	0	0.6	nc	(nc-nc)	<u>Liver and Intrahepatic Bile Ducts</u>				
Male	1	1.0	nc	(nc-nc)	<u>Lung and Bronchus</u>				
Female	0	0.2	nc	(nc-nc)	Male	2	6.8	nc	(nc-nc)
<u>Lung and Bronchus</u>					Female	3	4.3	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Burlington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	33	27.0	122.1	(84.1-171.5)	Male	20	18.1	110.7	(67.6-171.0)
Female	9	9.7	92.7	(42.3-176.0)	Female	17	14.2	119.8	(69.7-191.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	5.2	152.4	(65.6-300.3)	Male	9	4.7	189.6	(86.5-359.9)
Female	2	4.4	nc	(nc-nc)	Female	6	3.7	160.3	(58.5-349.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	20	15.7	127.6	(77.9-197.1)
Female	116	104.1	111.5	(92.1-133.7)	Female	15	13.0	115.7	(64.7-190.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	3.9	nc	(nc-nc)	Male	8	11.2	71.7	(30.9-141.3)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	26	31.4	82.9	(54.1-121.4)	Female	7	9.5	73.5	(29.5-151.5)
Female	30	30.9	96.9	(65.4-138.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	10	8.8	113.5	(54.3-208.8)
Male	3	7.3	nc	(nc-nc)	Female	11	9.5	115.9	(57.8-207.4)
Female	3	2.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	100	107.1	93.3	(75.9-113.5)
Male	3	2.3	nc	(nc-nc)	<u>Stomach</u>				
Female	3	1.8	nc	(nc-nc)	Male	7	6.3	111.3	(44.6-229.4)
<u>Kidney & Renal Pelvis</u>					Female	6	3.7	163.8	(59.8-356.6)
Male	18	14.8	121.7	(72.1-192.3)	<u>Testis</u>				
Female	8	8.6	92.5	(39.8-182.3)	Male	3	3.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	4.2	nc	(nc-nc)	Male	8	6.2	129.4	(55.7-255.0)
Female	0	1.3	nc	(nc-nc)	Female	19	18.9	100.5	(60.5-157.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	12	9.9	120.7	(62.3-210.9)	Female	28	24.4	114.6	(76.2-165.7)
Female	8	7.5	106.5	(45.9-209.9)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	385	371.1	103.8	(93.7-114.7)
Male	10	8.3	120.4	(57.6-221.5)	Female	381	359.3	106.0	(95.7-117.2)
Female	0	2.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	52	50.7	102.6	(76.6-134.6)					
Female	49	52.4	93.5	(69.1-123.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Cambridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	38	84.1	45.2	(32.0-62.0)	Male	50	59.6	83.9	(62.3-110.6)
Female	20	28.6	69.9	(42.7-108.0)	Female	47	50.7	92.6	(68.1-123.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	19	18.9	100.6	(60.6-157.2)	Male	18	14.5	124.2	(73.6-196.3)
Female	14	15.4	90.9	(49.6-152.5)	Female	11	11.0	100.1	(49.9-179.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	2.6	nc	(nc-nc)	Male	46	52.0	88.5	(64.8-118.1)
Female	291	314.3	92.6	(82.3-103.9)	Female	29	40.1	72.3	(48.4-103.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	9	14.4	62.5	(28.5-118.6)	Male	23	36.1	63.7	(40.4-95.6)
Female					Female	11	16.1	68.1	(34.0-121.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	83	99.7	83.3	(66.3-103.2)	Female	19	29.9	63.6	(38.3-99.4)
Female	87	94.3	92.2	(73.9-113.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	19	27.4	69.4	(41.8-108.4)
Male	6	22.4	26.7	(9.8-58.2)	Female	21	28.1	74.8	(46.3-114.3)
Female	4	5.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	279	320.9	86.9	(77.0-97.8)
Male	7	11.5	61.1	(24.5-125.8)	<u>Stomach</u>				
Female	6	9.2	64.9	(23.7-141.3)	Male	16	19.9	80.3	(45.9-130.4)
<u>Kidney & Renal Pelvis</u>					Female	8	11.3	70.8	(30.5-139.4)
Male	30	46.3	64.8	(43.7-92.5)	<u>Testis</u>				
Female	14	26.0	53.9	(29.5-90.5)	Male	21	22.0	95.3	(59.0-145.7)
<u>Larynx</u>					<u>Thyroid</u>				
Male	8	12.9	61.9	(26.6-121.9)	Male	27	22.6	119.6	(78.8-174.0)
Female	2	3.8	nc	(nc-nc)	Female	80	75.1	106.6	(84.5-132.7)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	16	33.7	47.4	(27.1-77.0)	Female	72	72.0	100.0	(78.2-125.9)
Female	25	24.2	103.5	(67.0-152.8)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	907	1175.6	77.2	(72.2-82.3)
Male	25	26.1	95.9	(62.0-141.5)	Female	960	1114.5	86.1	(80.8-91.8)
Female	15	8.4	178.3	(99.7-294.1)					
<u>Lung and Bronchus</u>									
Male	107	151.7	70.5	(57.8-85.2)					
Female	107	149.6	71.5	(58.6-86.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Canton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	26.9	78.2	(48.4-119.5)	Male	21	16.6	126.2	(78.1-192.8)
Female	7	10.3	67.7	(27.1-139.5)	Female	8	13.8	57.9	(24.9-114.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	4.8	nc	(nc-nc)	Male	3	4.5	nc	(nc-nc)
Female	4	4.3	nc	(nc-nc)	Female	6	3.9	154.0	(56.2-335.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.8	nc	(nc-nc)	Male	8	14.8	54.1	(23.3-106.5)
Female	98	99.9	98.1	(79.7-119.6)	Female	18	13.2	136.1	(80.6-215.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	3.6	nc	(nc-nc)	Male	6	10.4	57.6	(21.0-125.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	37	30.8	120.3	(84.7-165.8)	Female	7	9.4	74.8	(30.0-154.1)
Female	25	34.3	72.9	(47.1-107.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	11	8.6	128.2	(63.9-229.3)
Male	7	6.8	102.4	(41.0-211.0)	Female	10	10.3	97.1	(46.5-178.6)
Female	1	2.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	88	96.6	91.1	(73.1-112.2)
Male	2	1.9	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.7	nc	(nc-nc)	Male	4	6.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	4	4.2	nc	(nc-nc)
Male	8	13.3	60.0	(25.8-118.2)	<u>Testis</u>				
Female	9	8.4	107.7	(49.2-204.5)	Male	1	2.8	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	3.9	nc	(nc-nc)	Male	5	5.2	95.4	(30.7-222.6)
Female	0	1.2	nc	(nc-nc)	Female	25	17.1	145.9	(94.4-215.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	11	9.9	111.2	(55.4-198.9)	Female	22	22.5	97.6	(61.2-147.8)
Female	4	7.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	334	347.3	96.2	(86.1-107.0)
Male	6	7.8	77.2	(28.2-168.1)	Female	352	357.4	98.5	(88.5-109.3)
Female	0	2.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	51	47.2	108.1	(80.5-142.2)					
Female	59	51.3	114.9	(87.5-148.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;